Furthermore, about 30% of patients that develop resistance to aromatase inhibition (AI) respond to fulvestrant,50, 51 and in first‐line therapy for metastatic disease, the combination of fulvestrant and AI is superior to AI alone.52, 53. The gene discussed is CYP19A1; the disease is metastatic neoplasm.